Shanghai HeartCare Calls 2026 Class Meeting to Approve Non-Pre-Emptive Domestic Share Issuance

Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) just unveiled an announcement.

Shanghai HeartCare Medical Technology Corporation Limited has convened a 2026 class meeting of its unlisted shareholders on 16 January 2026 in Shanghai to seek approval for a proposed issuance of new domestic shares under a specific mandate. Shareholders will vote on the issuance itself, ratification of a subscription agreement with investor Zhang Han, authorization for the board to handle all matters related to the issuance, and confirmation that the new shares will be issued on a non-pre-emptive basis. The move, if approved, would provide the company with additional domestic capital and further flexibility in its capital structure, potentially diluting existing holdings of unlisted shareholders while supporting funding for ongoing business development.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H

Shanghai HeartCare Medical Technology Corporation Limited is a PRC-incorporated medical technology company listed in Hong Kong, focused on cardiovascular-related medical devices and technologies. It operates through both listed H shares and unlisted domestic shares, reflecting a dual-shareholding structure that targets investors in mainland China and international capital markets.

Average Trading Volume: 56,626

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.09B

For a thorough assessment of 6609 stock, go to TipRanks’ Stock Analysis page.